China Health Industries Holdings, Inc.

CHHE

US1693981045

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 03:59:45 2024-05-17 pm EDT			5-day change	1st Jan Change
1.45 ^USD	-21.62%		-29.27%	+197.44%

Apr. 01	China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022

November 04, 2022 at 12:10 pm EDT

China Health Industries Holdings, Inc. reported earnings results for the first quarter ended September 30, 2022. For the first quarter, the company reported net loss was USD 0.456445 million compared to USD 0.021387 million a year ago. Basic loss per share from continuing operations was USD 0.007 compared to USD 0.0003 a year ago.

Latest news about China Health Industries Holdings, Inc.

China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Apr. 01	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 21	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	Nov. 13	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-10	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-13	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-04	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-15	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-10	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-14	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-12	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	21-09-20	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021	21-05-14	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-02-10	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2020	20-10-13	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-05-15	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2019	20-02-14	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019	19-11-14	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2019	19-09-11	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2019	19-05-15	CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2018	19-02-14	CI
China Health Industries Holdings, Inc. Reports Unaudited Consolidated Financial Results for the Third Quarter and First Nine Months Ended March 31, 2015	15-05-15	CI

Chart China Health Industries Holdings, Inc.

Duration

Period

Chart China Health Industries Holdings, Inc.

More charts

Company Profile

China Health Industries Holdings, Inc. is a manufacturer of health food products. The Company's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The Company has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The Company's products are sold through sales agents.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHINA HEALTH INDUSTRIES HOLDINGS, INC.	+197.44%	95.03M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals